| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
John Sculley last filed a Form 4 in April 2025, as Director at CELU. The filings on record cover 3 companies. John Sculley's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 626,800 shares of ZETA. The ZETA filings lean toward selling, a net 261,969 shares.
John Sculley has 24 Form 4 filings on record from February 2015 to April 2025, across 3 companies: Director at Zeta Global (ZETA), 2021–2025; Director at Celularity (CELU), 2021–2023; Director at Salarius Pharmaceuticals (DCOY), 2015–2016.
The 54 reported transactions were 20 other transactions, 16 stock awards, 7 option or other derivative awards and 4 gifts, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $56K and 1 sale worth about $2.6M.
The only open-market purchase was 4,709 shares of DCOY at an average $11.92 on March 21, 2016, about $56K.
The only open-market sale was 261,969 shares of ZETA at an average $10.00 on June 14, 2021, about $2.6M. Twelve months later ZETA was down 34%.
Shares as reported in the last Form 4 for each company; the most recent is from April 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.